343 related articles for article (PubMed ID: 33710501)
1. Genetics of Triglyceride-Rich Lipoproteins Guide Identification of Pharmacotherapy for Cardiovascular Risk Reduction.
Shaik A; Rosenson RS
Cardiovasc Drugs Ther; 2021 Jun; 35(3):677-690. PubMed ID: 33710501
[TBL] [Abstract][Full Text] [Related]
2. Genetics and causality of triglyceride-rich lipoproteins in atherosclerotic cardiovascular disease.
Rosenson RS; Davidson MH; Hirsh BJ; Kathiresan S; Gaudet D
J Am Coll Cardiol; 2014 Dec; 64(23):2525-40. PubMed ID: 25500239
[TBL] [Abstract][Full Text] [Related]
3. Triglyceride-rich lipoproteins as a causal factor for cardiovascular disease.
Toth PP
Vasc Health Risk Manag; 2016; 12():171-83. PubMed ID: 27226718
[TBL] [Abstract][Full Text] [Related]
4. Residual Cardiovascular Risk at Low LDL: Remnants, Lipoprotein(a), and Inflammation.
Hoogeveen RC; Ballantyne CM
Clin Chem; 2021 Jan; 67(1):143-153. PubMed ID: 33257928
[TBL] [Abstract][Full Text] [Related]
5. The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk.
Sandesara PB; Virani SS; Fazio S; Shapiro MD
Endocr Rev; 2019 Apr; 40(2):537-557. PubMed ID: 30312399
[TBL] [Abstract][Full Text] [Related]
6. Lipoprotein Lipase: Is It a Magic Target for the Treatment of Hypertriglyceridemia.
Moon JH; Kim K; Choi SH
Endocrinol Metab (Seoul); 2022 Aug; 37(4):575-586. PubMed ID: 36065644
[TBL] [Abstract][Full Text] [Related]
7. [Features of hypertriglyceridemia in chronic kidney disease(CKD)].
Saito T
Nihon Rinsho; 2013 Sep; 71(9):1618-22. PubMed ID: 24205724
[TBL] [Abstract][Full Text] [Related]
8. Differential binding of triglyceride-rich lipoproteins to lipoprotein lipase.
Xiang SQ; Cianflone K; Kalant D; Sniderman AD
J Lipid Res; 1999 Sep; 40(9):1655-63. PubMed ID: 10484612
[TBL] [Abstract][Full Text] [Related]
9. Triglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular Disease: New Insights From Epidemiology, Genetics, and Biology.
Nordestgaard BG
Circ Res; 2016 Feb; 118(4):547-63. PubMed ID: 26892957
[TBL] [Abstract][Full Text] [Related]
10. [Current progress in lipoprotein lipase and atherosclerosis].
Tian GP; Chen WJ; He PP; Yin WD; Tnag CK
Sheng Li Ke Xue Jin Zhan; 2012 Oct; 43(5):345-50. PubMed ID: 23316606
[TBL] [Abstract][Full Text] [Related]
11. The Roles of ApoC-III on the Metabolism of Triglyceride-Rich Lipoproteins in Humans.
Borén J; Packard CJ; Taskinen MR
Front Endocrinol (Lausanne); 2020; 11():474. PubMed ID: 32849270
[TBL] [Abstract][Full Text] [Related]
12. Remnants of the Triglyceride-Rich Lipoproteins, Diabetes, and Cardiovascular Disease.
Chait A; Ginsberg HN; Vaisar T; Heinecke JW; Goldberg IJ; Bornfeldt KE
Diabetes; 2020 Apr; 69(4):508-516. PubMed ID: 32198194
[TBL] [Abstract][Full Text] [Related]
13. Targeting triglycerides to lower residual cardiovascular risk.
Bubb KJ; Nelson AJ; Nicholls SJ
Expert Rev Cardiovasc Ther; 2022 Mar; 20(3):185-191. PubMed ID: 35323080
[TBL] [Abstract][Full Text] [Related]
14. Association of triglyceride-rich lipoproteins-related markers and low-density lipoprotein heterogeneity with cardiovascular risk: effectiveness of polyacrylamide-gel electrophoresis as a method of determining low-density lipoprotein particle size.
Tani S; Matsumoto M; Nagao K; Hirayama A
J Cardiol; 2014 Jan; 63(1):60-8. PubMed ID: 24016623
[TBL] [Abstract][Full Text] [Related]
15. Triglyceride-Rich Lipoprotein Remnants and Cardiovascular Disease.
Duran EK; Pradhan AD
Clin Chem; 2021 Jan; 67(1):183-196. PubMed ID: 33409533
[TBL] [Abstract][Full Text] [Related]
16. Emerging Evidence that ApoC-III Inhibitors Provide Novel Options to Reduce the Residual CVD.
Taskinen MR; Packard CJ; Borén J
Curr Atheroscler Rep; 2019 May; 21(8):27. PubMed ID: 31111320
[TBL] [Abstract][Full Text] [Related]
17. Apolipoprotein C-II: New findings related to genetics, biochemistry, and role in triglyceride metabolism.
Wolska A; Dunbar RL; Freeman LA; Ueda M; Amar MJ; Sviridov DO; Remaley AT
Atherosclerosis; 2017 Dec; 267():49-60. PubMed ID: 29100061
[TBL] [Abstract][Full Text] [Related]
18. [Triglyceride (TG) and remnant lipoproteins].
Yoshida H; Kisugi R; Koike M; Kurosawa H
Rinsho Byori; 2012 Apr; 60(4):343-8. PubMed ID: 22686044
[TBL] [Abstract][Full Text] [Related]
19. Omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid and their mechanisms of action on apolipoprotein B-containing lipoproteins in humans: a review.
Oscarsson J; Hurt-Camejo E
Lipids Health Dis; 2017 Aug; 16(1):149. PubMed ID: 28797250
[TBL] [Abstract][Full Text] [Related]
20. Triglycerides and heart disease: still a hypothesis?
Goldberg IJ; Eckel RH; McPherson R
Arterioscler Thromb Vasc Biol; 2011 Aug; 31(8):1716-25. PubMed ID: 21527746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
